U.S. markets close in 13 minutes
  • S&P 500

    3,885.45
    -16.37 (-0.42%)
     
  • Dow 30

    31,486.16
    -49.35 (-0.16%)
     
  • Nasdaq

    13,417.73
    -171.10 (-1.26%)
     
  • Russell 2000

    2,241.49
    -33.83 (-1.49%)
     
  • Crude Oil

    59.56
    -1.08 (-1.78%)
     
  • Gold

    1,734.70
    +11.70 (+0.68%)
     
  • Silver

    26.85
    +0.17 (+0.64%)
     
  • EUR/USD

    1.2093
    +0.0034 (+0.28%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • GBP/USD

    1.3968
    +0.0048 (+0.34%)
     
  • USD/JPY

    106.7410
    +0.0110 (+0.01%)
     
  • BTC-USD

    47,406.23
    -758.84 (-1.58%)
     
  • CMC Crypto 200

    947.46
    -39.19 (-3.97%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Sage Therapeutics to Present at Upcoming November Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the following investor conferences in November:

  • Stifel Virtual Healthcare Conference: fireside chat on Monday, November 16, 2020 at 8:40 am ET.

  • Wolfe Research Virtual Healthcare Conference: fireside chat on Thursday, November 19, 2020 at 4:05 pm ET.

A live webcast of each presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcasts will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005213/en/

Contacts

Investors
Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Media
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com